ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurodevelopmental Disorders in Children With Congenital Heart Disease (NeuroDis-CHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03360370
Recruitment Status : Recruiting
First Posted : December 4, 2017
Last Update Posted : April 25, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Lille

November 28, 2017
December 4, 2017
April 25, 2018
December 6, 2017
June 2019   (Final data collection date for primary outcome measure)
Percentage of children classified "at risk" for neuro-developmental disorders by the Age & Stage Questionnaire Third Edition in French (ASQ3) score [ Time Frame: Baseline: one session ]
The ASQ3 evaluates neurodevelopment in children by a parental questionnaire. ASQ-3 score screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's skills are evaluated. Each item could be range between Yes (The child do the action - 10 points), Sometimes (5 points) or Not yet (0 point). The scale for each areas could be from 0 (worse outcome) to 60 points (best outcome). The different areas scores are referred in a chart specific of each questionnaire. In each area the score indicates if the child's development appears to be on schedule (best outcome), need learning and attention or need to be evaluated by a professional (worse outcome, - 2 SD from the global population).
Percentage of children classified at risk of neuro-developmental difficulties by the ASQ score [ Time Frame: Baseline: one session ]
The ASQ score screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.
Complete list of historical versions of study NCT03360370 on ClinicalTrials.gov Archive Site
  • Frequency of neurodevelopmental disorders in children with congenital heart disease in this screened population [ Time Frame: Baseline: one session ]
    Number of children depicted with neurodevelopmental delays in comparison to children who do not have neurodevelopmental delays in the screened population
  • Frequency of neurodevelopmental disorders according to the severity of congenital heart disease [ Time Frame: Baseline: one session ]
    Children with neurodevelopmental disorders are classified according to the severity of the congenital heart disease ( mild, moderate or severe congenital heart disease). The percentage of children with neurodevelopmental disorders in each category is established and compared to the others.
  • Number of Children With Documented Risk Factors for neurodevelopmental disorders [ Time Frame: Baseline: one session ]
    The number of children with documented risk factors for neurodevelopmental disorders among neonatal data characteristics of congenital heart disease and first surgery, and comorbidities is evaluated
  • Ratio of children with neurodevelopmental disorders and for whom specific care was implemented [ Time Frame: Baseline: one session ]
    The ratio of children with neurodevelopmental disorders for whom specific care was implemented /children with neurodevelopmental disorders who do not have specific care despite neurodevelopmental disorders is established
  • Frequency for neurodevelopmental disorders in children with congenital heart disease in this screened population [ Time Frame: Baseline: one session ]
    Number of children depicted with neurodevelopmental delays in comparison with children who did not have have neurodevelopmental delays in the screened population
  • Frequency for neurodevelopmental disorders according to the severity of congenital heart disease [ Time Frame: Baseline: one session ]
    Children with neurodevelopmental disorders are classify according to the severity of the congenital heart disease ( mild, moderate or severe congenital heart disease). Percentage of children with neurodevelopmental disorders in each category is established and compare with the others.
  • Number of Children With Documented Risk Factors for neurodevelopmental disorders [ Time Frame: Baseline: one session ]
    among neonatal data characteristics of congenital heart disease and first surgery, and comorbidities
  • Ratio of children with neurodevelopmental disorders and for whom specific care was implemented [ Time Frame: Baseline: one session ]
    This ratio is evaluated in comparison with those who did not have specific care despite neurodevelopmental disorders)
Not Provided
Not Provided
 
Neurodevelopmental Disorders in Children With Congenital Heart Disease
Screening for Neurodevelopmental Disorders in Children With Congenital Heart Disease Aged From 6 to 66 Months in Nord-Pas-de-Calais

Children with congenital heart disease are at risk for neurodevelopmental disorders, these disorders impacting their quality of life and their integration into society.

The aim of this study is to detect neurodevelopmental disorders in children (aged from 6 to 66 months) with congenital heart disease in Nord-Pas-De-Calais (France) and to evaluate the frequency and risk factors of these neurodevelopmental disorders for a better follow-up.

This study will help implementing a specific program for the evaluation and management of neurodevelopmental disorders in children suffering from congenital heart disease in Nord-Pas-De-Calais and more globally, in the region Hauts-De-France.

Are selected children with "significant" congenital heart disease (aged from 6 to 66 months) in "Nord-Pas-De-Calais" fulfilling inclusion criteria. A reliable and valid questionnaire used to screen developmental delays of children aged from one month to 66 months is completed by volunteer parents at the time of the study. Data of the questionnaire is collected and a scoring by professional is provided ; children at risk for neurodevelopmental delays are depicted.

In parallel, medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders.

The frequency of neurodevelopmental disorders in this screened population according to risk factors (among neonatal data, severity of congenital heart disease, surgery, length of stay at hospital,... ) will be evaluated. The ratio children with neurodevelopmental disorders for whom specific care was implemented/ children with neurodevelopmental disorders who did not have specific care despite neurodevelopmental disorders will be established.

Follow-up action will be taken for children at risk for developping neurological disorders highlighted by the screening.

This study will help implementing a specific program for evaluation and management of neurodevelopmental disorders for children with congenital heart disease in our region.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Children With Congenital Heart Disease
Congenital Heart Disease
Other: Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)

This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.

It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities.

6 to 66 months children with significant CHD
Children with "significant" congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays.
Intervention: Other: Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
233
Same as current
June 2019
June 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children aged 6 to 66 months at the time of study
  • living in region "Nord-Pas-De-Calais"
  • with " significant" congenital heart disease (= complex congenital heart diseases operated or not, simple or moderate congenital heart disease who had cardiac surgery)
  • Followed by the Pediatric Cardiology Department of Lille University Hospital, or patients having a cardiopediatric follow-up outside Lille University Hospital but having been taken in charge at the University Hospital of Lille for any reason (cardiac or not)

Exclusion Criteria:

Children :

  • lost to sight
  • Deceased
  • with congenital heart disease, living in Nord-Pas-de-Calais but never having been taken in charge at Lille University Hospital
  • with mild or moderate congenital heart disease not having undergone surgery or having only undergone cardiac catheterization
  • with cardiac surgery not performed in the Centers of Jacques CARTIER and Marie LANNNELONGUE
Sexes Eligible for Study: All
6 Months to 66 Months   (Child)
No
Contact: Marie-Paule GUILLAUME, MD 3 20 44 69 49 ext +33 Marie-Paule.Guillaume@CHRU-lille.fr
France
 
 
NCT03360370
2017_31
2017-A01839-44. ( Other Identifier: ID-RCB number, ANSM )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
University Hospital, Lille
University Hospital, Lille
Not Provided
Principal Investigator: Marie-Paule GUILLAUME, MD University Hospital, Lille
University Hospital, Lille
December 2017